恩替卡韦胶囊与拉米夫定治疗慢性乙型肝炎的对照研究  被引量:7

Comparative analysis of the efficacies of entecavir capsules and lamivudine in chronic hepatitis B patients

在线阅读下载全文

作  者:徐道振[1] 蔡晧东[1] 马秀云[1] 李跃旗[2] 陆宪中[3] 俞海英[4] 孙爱民 赵龙凤[6] 张缭云[2] 高晓宏 

机构地区:[1]首都医科大学附属北京地坛医院肝病科,100015 [2]解放军第三○二医院肝病科 [3]济南市传染病医院肝病科 [4]南京市第二医院肝病科 [5]河南省医药科学研究院肝病科 [6]山西医科大学第一医院感染病科 [7]江西青峰药业有限公司

出  处:《中华肝脏病杂志》2013年第12期886-890,共5页Chinese Journal of Hepatology

摘  要:目的探讨恩替卡韦胶囊治疗慢性乙型肝炎的安全性和有效性。方法采用多中心、随机、双盲、阳性药物平行对照的研究方法,为期96周,共有232例患者入组。前48周按1:1比例随机给予恩替卡韦(ETV)0.5mg/d,或拉米夫定(LAM)100mg/d。48周双盲治疗期结束后,进入开放性ETV胶囊0.5mg/d治疗,观察至96周。计量资料符合正态分布者用方差分析和f检验,不符合正态分布者用秩和检验方法进行统计分析。计数资料采用χ2检验进行比较。结果服药48周后,病毒学完全应答率(HBVDNA〈500拷贝/ml,PCR法),ETV组和LAM组分别为90.3%和59.4%;病毒学反弹发生率分别为1.9%和13.9%。服药96周后,病毒学完全应答率,ETV组和LAM组分别为86.0%和71.4%;但HBVDNA〉5 log10拷贝/ml的患者,ETV组仅1例(1.2%),LAM组有10例(11.9%),两组差异有统计学意义(P=0.005)。结论ETV胶囊能迅速持续抑制HBV的复制,且耐药发生率低,长期治疗慢性乙型肝炎其疗效优于LAM。Objective To investigate the efficacy profile of entecavir capsule (ETV) as a chronic hepatitis B therapy, as compared to lamivudine (LAM). Methods In this multicenter, randomized, double-blind, parallel group evaluation of ETV, 232 subjects were administered a 96-week course of 0.5 mg/day ETV or 100 mg/day LAM. PCR measurement of hepatitis B virus (HBV) was conducted throughout the treatment course to determine achievement of complete virologic response (CVR; defined as 〈 500 copies/ml of HBV DNA) or experience of virology rebound (〉 500 copies/ml of HBV DNA after achievement of CVR). Results After week-48 of treatment, the ETV group showed a higher CVR rate (90.3% vs. LAM: 59.4%) and lower virology rebound rate (1.9% vs. LAM: 13.9%). After week-96 of treatment, the ETV group continued to have a higher CVR rate (86.0% vs. LAM: 71.4%), and virology rebound was experienced by significantly less subjects in the ETV group (1.2% vs. LAM: 11.9%, P = 0.005). Conclusion ETV therapy can quickly and continuously suppress HBV replication in chronic hepatitis B patients, and has a lower resistance rate than LAM. Compared to LAM, ETV may be a superior long-term treatment choice for chronic hepatitis B.

关 键 词:肝炎病毒 乙型 肝炎 乙型 慢性 拉米夫定 临床试验 恩替卡韦 

分 类 号:R512.62[医药卫生—内科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象